



GIOSTAR, A CELL THERAPY AND RESEARCH INSTITUTION, IS LEADING DEVELOPMENT OF THERAPIES FOR CANCER, METABOLIC AND DEGENERATIVE DISEASES

DR. ANAND SRIVASTAVA
CHAIRMAN AND CSO, GIOSTAR



GIOSTAR is the world's leading stem cell research institution located in San Diego, California, USA, and has been involved in stem cell research work for over 20 years. GIOSTAR's team of scientists and clinicians has been involved in the development and utilization of clinical protocols related to stem cell transplants. They have the capability to treat several devastating immunological diseases and blood-related diseases. These include Diabetes Type I and Type II, Lupus, Multiple Sclerosis, Crohn's disease, Vasculitis, Scleroderma, Myasthenia Gravis, Sickle Cell Anemia, Leukemia, Lymphoma, Thalassemia and developing the therapies for Alzheimer's disease, autism, anti-aging treatments, Parkinson's disease, cancer, heart, and retinal degeneration, amyotrophic lateral sclerosis, neuropathy, osteoarthritis, paralysis, strokes, spinal cord injuries, skin burns and spinal muscular atrophy (SMA).

The company uses adult stem cells for its autologous and allogeneic stem cell therapy to treat patients. They have also generated blood stem cells from stem cells, which may have abilities to manage blood-related diseases such as beta-thalassemia and sickle cell anemia. Today, the company is a leading private organization with state-of-the-art excellence

in the extraction of stem cells from the human body for therapeutic application.

Their patients normally suffer from metabolic diseases, cancer, and degenerative diseases. GIOSTAR has developed clinical protocols of stem cell therapies for treating autoimmune, degenerative, and metabolic diseases. They have also developed immune-therapy protocols for treating cancer.

ABOUT THE CHAIRMAN

Dr. Anand Srivastava is the Chairman and Chief Scientific Officer (CSO) of GIOSTAR. His success is rooted in his unique background of expertise in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cells, tissue targeting, gene therapy, and clinical research. He has been associated with leading universities and research institutes in the USA. While working at the University of California San Diego (UCSD), University of California Irvine (UCI), Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute, and University of California Los Angeles (UCLA), USA, he has helped develop several research programs and has an extensive research experience

in the field of stem cell science, which is documented by several publications in revered scientific journals. Dr. Srivastava is also the leader of Celebration Life Sciences, a firm that is currently in the process of clinical trials for diabetes using stem cells.

OVERCOMING CHALLENGES

The company strongly believes in teamwork with harmony, which is essential for the success of any institution. "In any business, problems are inevitable and we at GIOSTAR never worry or become overly stressed with problems, as we expect them to come. We have a dedicated team with strong leadership skills that have helped us sail through the pandemic. We helped many patients during the COVID-19 pandemic and saved the lives of several patients using our stem cell technology," says Dr. Srivastava.

The GIOSTAR team includes international leaders in the field of adult stem cells, embryonic stem (ES) cells, induced pluripotent stem (iPS) cell research and technologies. Their team was the first to demonstrate the significance of ES cell use for the development of therapies for several degenerative diseases related to tissue and organs. The publications of these therapies have been thoroughly investigated and documented by many noted journals of medicine. GIOSTAR is leading the most advanced research in the field of ES cells and iPS cells to develop new therapies for future clinical use.

BUILDING THE COMPANY

Dr. Srivastava believes that life is a struggle. Born in a doctor's family, he saw his father, a leading cardiologist in India (who is his real inspiration) helping and treating patients unconditionally. He realized that doctors have limited options to treat critically ill patients suffering particularly from metabolic diseases. He decided to work on it and started his scientific life with gene therapy. Although gene therapy is one of the most effective ways to treat metabolic diseases, the clinical setup and long-term management are extremely complex. Given these constraints, he began work on stem cell science.

He says, "Twenty years ago, working at the University of San Diego California (UCSD), it occurred to me that stem cells could present a highly effective way to treat damaged or degenerating organs. Working in collaboration with a few researchers, I started this field and now we have scientists all over the world working on it. With every passing day, new findings are emerging that point to the power of stem cells to manage metabolic diseases and repair damaged organs. I believe this is the way that the present and future medical science is going to progress."

He adds, "Establishing new science and persuading physicians, researchers, and others in the medical and

research communities have been a very arduous undertaking, given the widespread resistance and misconception about stem cells. The struggle is always there, but truthful efforts always win the day."

As a leader, he believes in the decentralization of powers and listening to the viewpoints of all team members. Considering all perspectives allows them to all flourish together. "I make it a priority to listen to our team members to help guide decisions for the collective progress of the group," he says. The company keeps things transparent and treats everyone as a family member.

FUTURE ENDEAVORS

The best way to ensure the success of any business is to provide the best customer service. GIOSTAR treats every customer with softness and tries to solve their problem with utmost sincerity. Currently, the company is in a process of developing stem cell-based treatments of diabetes, COVID-19, and long COVID issues. "We are under the process of developing treatments using stem cells. We are working to bring 6 stem cell companies public. We are waiting for approval from the U.S. Food and Drug Administration (FDA) for the treatment of diabetes and other autoimmune diseases using stem cells. We are under the process of developing natural red blood cells to solve the problem of blood transfusion and blood-related diseases," he asserts.

The company has generated pure neural precursor cells (NPCs) which may be used to treat many neural diseases. Also, it is leading in the field of generating patient-specific pluripotent stem cells (iPSCs), which have the ability to differentiate into cells of any lineage. These cells have the potential to be used as an alternative to adult stem cells. The company is also working to unfold the mystery of the biology of aging and become the world leader in aging management technologies and therapeutics (commonly referred to as "anti-aging"). In this paradigm, patients would utilize its aging management services as proactive, preventative stem cell therapies against debilitating diseases associated with the increasing aging population.

Recently, GIOSTAR collaborated with India's current prime minister Shri Narendra Modi (then Chief Minister of the State of Gujarat) to inaugurate the world's first, state-of-the-art private hospital in India. The institution received significant funding from the government of Gujarat, India.

Dr. Anand Srivastava concludes by saying, "Always think critically and logically about everything. In managing health-related problems, no medicine can serve as a substitute for a healthy lifestyle. To keep a healthy lifestyle, practice yoga and do exercise. Resort to medicines only when it is truly necessary."